FDA Updates EUA for Sotrovimab

4/5/22 — The FDA has again revised its EUA for sotrovimab to treat COVID-19. According to CDC data, Omicron sub-variant BA.2 now accounts for more than 50 percent of COVID-19 cases in every HHS region in the U.S.  Since the authorized dose of sotrovimab is unlikely to be effective against this sub-variant, FDA has withdrawn authorization and recommends the healthcare providers use other approved or authorized products to treat patients with COVID-19. Read the FDA announcement.